Skip to main content

Research & Treatments

Cancer Today
AdvocacyResearchStories

Redefining Cancer Survivorship

*May 2025* As people with advanced disease live longer, they face physical and mental health side effects. Patient advocates say research and care must focus on their unique needs. WHEN JILL FELDMAN’S FATHER was diagnosed with lung cancer in the early 1980s, he lived just three months after his diagnosis. Fifteen…
laurabbook@gmail.com
November 19, 2025
EGFR Resister Logo
ResearchResourcesTreatments

Project PRIORITY

*April 2025*   Project PRIORITY (Patient-Reported Initiative on Resistance, Incidence, Treatment, studY survey) was an online survey completed in 2019 by people living with EGFR lung cancer. We are excited to share the launch of our new interactive tool that brings Project PRIORITY survey data to life - highlighting the…
laurabbook@gmail.com
November 19, 2025
Blossom Hill Therapeutics logo
ResearchTreatments

Design and discovery of BH-30643: A novel, reversible, mutant-selective macrocyclic EGFR inhibitor invulnerable to common resistance mutations

*April 2025* Note: The following is an abstract from AACR 2025 presenting data on this new clinical trial, SOLARA (NCT06706076) Outcomes on tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC fall short of the durable benefit observed with next-generation targeted therapies in ALK and ROS1-driven NSCLC. We reviewed the chemical structures of 30+ existing…
laurabbook@gmail.com
November 19, 2025
Stock Titan logo
ResearchTreatments

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

*April 2025* Note: This drug is in the pipeline and is planning to open Phase 1 clinical trials in mid-2025. ALX Oncology (ALXO) has received FDA clearance for its Investigational New Drug (IND) application for ALX2004, a potential first-in-class antibody-drug conjugate (ADC) for treating EGFR-expressing solid tumors. The company plans to initiate Phase…
laurabbook@gmail.com
November 19, 2025
MEDPAGE TODAY
ResearchTreatments

Novel TKI Highly Active in HER2-Mutant Lung Cancer

*April 2025* The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC) in a multicohort phase Ia/Ib study. In the first cohort of 75 patients with tumors harboring a mutation in the tyrosine kinase domain, the confirmed objective response rate…
laurabbook@gmail.com
November 19, 2025
IASLC
ResearchTreatments

AACR 2025 Highlights

*April 2025* In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Christine Lovly discuss the significant lung cancer findings presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting.  They discuss the results from the Beamion LUNG-1 trial, a phase 1a/1b dose escalation trial with…
laurabbook@gmail.com
November 19, 2025